Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
29 July 2016
|
| In: |
Blood cancer journal
Year: 2016, Volume: 6 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/bcj.2016.46 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1038/bcj.2016.46 Verlag, Volltext: https://www.nature.com/articles/bcj201646 
|
| Author Notes: | S. Kayser, A. Benner, C. Thiede, U. Martens, J. Huber, P. Stadtherr, J.W.G. Janssen, C. Röllig, M.J. Uppenkamp, T. Bochtler, U. Hegenbart, G. Ehninger, A.D. Ho, P. Dreger and A. Krämer |
| Summary: | The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight of the 67 patients had a FLT3-ITD (42%). Median age at transplantation was 54.7 years, median follow-up for survival from time of allografting was 4.9 years. At transplantation, 31 patients were in first, 20 in second complete remission (CR) and 16 had refractory disease (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR patients. Overall survival (OS) for patients transplanted in CR was significantly longer as compared to patients with RD (P=0.004), irrespective of whether the patients were transplanted in first or second CR (P=0.74). There was a highly significant difference in OS after allogeneic HSCT between pre-transplant MRD-positive and MRD-negative patients (estimated 5-year OS rates of 40 vs 89%; P=0.007). Multivariable analyses on time to relapse and OS revealed pre-transplant NPM1 MRD levels >1% as an independent prognostic factor for poor survival after allogeneic HSCT, whereas FLT3-ITD had no impact. Notably, outcome of patients with pre-transplant NPM1 MRD positivity >1% was as poor as that of patients transplanted with RD. |
|---|---|
| Item Description: | Gesehen am 11.02.2019 Im Titel ist "NPM1" kursiv geschrieben |
| Physical Description: | Online Resource |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/bcj.2016.46 |